Search results

Found 16 matches for

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.

Unrecognizable Senior old woman walking alone with walker on the city street, elderly and disability concept

News Items (16)

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

11 March 2021

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

8 March 2021

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

A more tailored approach to treating psoriatic arthritis

8 January 2021

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

New breakthrough in the treatment of rheumatoid arthritis

25 November 2020

People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.

Key discovery in Psoriatic Arthritis points way for developing targeted treatments

21 September 2020

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease.

Workload linked with an increased risk of knee osteoarthritis

9 September 2020

Men and women working in heavy manual occupations are twice as likely to suffer from knee osteoarthritis (OA), the most common joint disorder, compared to those in sedentary occupations according to a new study published in the prestigious journal Seminars in Arthritis and Rheumatism.

Numerous jobs linked to increased risk of knee osteoarthritis

23 July 2020

Stay-at-home parents, cleaners, and blue-collar workers found to be more likely to develop osteoarthritis

Joint cell discovery offers new hope for people with rheumatoid arthritis

29 June 2020

The key to swift treatments to cure the pain of rheumatoid arthritis has been found in the joints of people with the condition who are in long- term remission.

Researchers identify markers in joint fluid that could be the key to cartilage repair

9 March 2020

Molecular changes in the joint fluid during surgical joint distraction reveal markers that may drive cartilage repair in osteoarthritis.

New therapeutic target identified in spondyloarthritis

20 January 2020

A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.

Key link discovered between tissue cell type and different forms of arthritis

29 May 2019

Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.

Study reveals new drug target for rheumatoid arthritis

28 May 2019

New research at the Kennedy Institute reveals potential of a novel class of drugs for the treatment of rheumatoid arthritis.

UKRI Future Leaders Fellowship to Dr Fiona Watt

7 May 2019

Dr Fiona Watt has been awarded a prestigious UK Research and Innovation (UKRI) Future Leaders Fellowship to further her research for better treatments for people living with, or at risk of the commonest form of arthritis, osteoarthritis.

New approach could bring closer a cure for a painful form of arthritis

1 April 2019

Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).

Showcasing a new approach to arthritis research

27 March 2019

A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).

New drug class could offer a targeted safer treatment alternative for patients with rheumatoid arthritis

15 February 2019

A new treatment targeting tenascin-C could reduce the progression and severity of rheumatoid arthritis (RA) at the very early stages of disease.

Meet the Kennedy team

Tonia Vincent

Professor of Musculoskeletal Biology

Read the paper

Active immunization targeting Nerve Growth Factor attenuates chronic pain behavior in murine osteoarthritis

Annals of Rheumatic Disease, 12 March 2019. doi: 10.1136/annrheumdis-2018-214489

Full paper

In collaboration with

The Jenner Institute

Professor Martin Bachmann's Lab, University of Bern

Latvian Biomedical Research & Study Centre

Supported by

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Professor Katja Simon elected to the Academy of Medical Sciences

12 May 2021

Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.

3,400 different medicines used globally to treat COVID-19

11 May 2021

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

6 May 2021

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

5 May 2021

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

4 May 2021

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

30 April 2021

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?